Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naloxegol for Refractory Constipation in ICU
NCT02705378Phase 3Withdrawn
- Sponsor
- Massachusetts General Hospital
- Start
- May 2017
- Primary completion
- Apr 2019
- Modality
- Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 3 trial of naloxegol in opioid-induced constipation (OIC), sponsored by Massachusetts General Hospital. Planned start May 2017; status: withdrawn.
02
Drugs
naloxegol
03
Conditions
opioid-induced constipation (OIC)
Beyond the preview
Go deeper on NCT02705378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02705378.